{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T04:04:49Z","timestamp":1778645089631,"version":"3.51.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s10549-026-07935-3","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T08:02:37Z","timestamp":1772870557000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative effectiveness of CDK4\/6 inhibitors in metastatic breast cancer: using the target trial emulation framework to investigate overall survival in routine care"],"prefix":"10.1007","volume":"216","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8080-7960","authenticated-orcid":false,"given":"Adam M.","family":"Brufsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2494-2126","authenticated-orcid":false,"given":"Richard S.","family":"Finn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0792-0320","authenticated-orcid":false,"given":"Otto","family":"Metzger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3513-0214","authenticated-orcid":false,"given":"Rodrigo","family":"Goncalves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2003-2213","authenticated-orcid":false,"given":"Cynthia","family":"Huang-Bartlett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5785-8815","authenticated-orcid":false,"given":"Sameet","family":"Sreenivasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8203-7226","authenticated-orcid":false,"given":"Ula","family":"Nur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Davies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6723-8695","authenticated-orcid":false,"given":"Alex","family":"Grigorenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4074-4536","authenticated-orcid":false,"given":"Gr\u00e1inne H.","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,7]]},"reference":[{"issue":"12","key":"7935_CR1","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari A, Andr\u00e9 F, Barrios CH, Cort\u00e9s J, de Azambuja E, DeMichele A et al (2021) ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol 32(12):1475\u20131495. https:\/\/doi.org\/10.1016\/j.annonc.2021.09.019","journal-title":"Ann Oncol"},{"issue":"12","key":"7935_CR2","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1200\/jco.24.00248","volume":"42","author":"HJ Burstein","year":"2024","unstructured":"Burstein HJ, DeMichele A, Fallowfield L, Somerfield MR, Henry NL, Biomarker Testing and Endocrine and Targeted Therapy in Metastatic Breast Cancer Expert Panels (2024) Endocrine and targeted therapy for hormone receptor\u2013positive, human epidermal growth factor receptor 2\u2013negative metastatic breast cancer\u2014capivasertib-fulvestrant: ASCO rapid recommendation update. J Clin Oncol 42(12):1450\u20131453. https:\/\/doi.org\/10.1200\/jco.24.00248","journal-title":"J Clin Oncol"},{"key":"7935_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2024.103756","volume":"76","author":"F Cardoso","year":"2024","unstructured":"Cardoso F, Paluch-Shimon S, Schumacher-Wulf E, Matos L, Gelmon K, Aapro M et al (2024) 6th and 7th international consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7). Breast 76:103756. https:\/\/doi.org\/10.1016\/j.breast.2024.103756","journal-title":"Breast"},{"issue":"20","key":"7935_CR4","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K et al (2016) Palbociclib and letrozole in advanced breast cancer. N Engl J Med 375(20):1925\u20131936. https:\/\/doi.org\/10.1056\/NEJMoa1607303","journal-title":"N Engl J Med"},{"issue":"18","key":"7935_CR5","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","volume":"375","author":"GN Hortobagyi","year":"2016","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S et al (2016) Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 375(18):1738\u20131748. https:\/\/doi.org\/10.1056\/NEJMoa1609709","journal-title":"N Engl J Med"},{"issue":"32","key":"7935_CR6","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","volume":"35","author":"MP Goetz","year":"2017","unstructured":"Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J et al (2017) MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol 35(32):3638\u20133646. https:\/\/doi.org\/10.1200\/JCO.2017.75.6155","journal-title":"J Clin Oncol"},{"issue":"1","key":"7935_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","volume":"16","author":"RS Finn","year":"2015","unstructured":"Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO et al (2015) The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study. Lancet Oncol 16(1):25\u201335. https:\/\/doi.org\/10.1016\/S1470-2045(14)71159-3","journal-title":"Lancet Oncol"},{"key":"7935_CR8","unstructured":"US Food and Drug Administration: Resources for Information | Approved Drugs. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/resources-information-approved-drugs (2022). Accessed April 3, 2025."},{"issue":"10","key":"7935_CR9","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1056\/NEJMoa2114663","volume":"386","author":"GN Hortobagyi","year":"2022","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Hart L et al (2022) Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med 386(10):942\u2013950. https:\/\/doi.org\/10.1056\/NEJMoa2114663","journal-title":"N Engl J Med"},{"issue":"9","key":"7935_CR10","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1200\/JCO.23.00137","volume":"42","author":"DJ Slamon","year":"2024","unstructured":"Slamon DJ, Dieras V, Rugo HS, Harbeck N, Im SA, Gelmon KA et al (2024) Overall survival with palbociclib plus letrozole in advanced breast cancer. J Clin Oncol 42(9):994\u20131000. https:\/\/doi.org\/10.1200\/JCO.23.00137","journal-title":"J Clin Oncol"},{"issue":"8","key":"7935_CR11","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.annonc.2024.04.013","volume":"35","author":"MP Goetz","year":"2024","unstructured":"Goetz MP, Toi M, Huober J, Sohn J, Tr\u00e9dan O, Park IH et al (2024) Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3. Ann Oncol 35(8):718\u2013727. https:\/\/doi.org\/10.1016\/j.annonc.2024.04.013","journal-title":"Ann Oncol"},{"issue":"1","key":"7935_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-53151-8","volume":"14","author":"C Kappel","year":"2024","unstructured":"Kappel C, Elliott MJ, Kumar V, Nadler MB, Desnoyers A, Amir E (2024) Comparative overall survival of CDK4\/6 inhibitors in combination with endocrine therapy in advanced breast cancer. Sci Rep 14(1):3129. https:\/\/doi.org\/10.1038\/s41598-024-53151-8","journal-title":"Sci Rep"},{"issue":"1","key":"7935_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11322-2","volume":"23","author":"Y Liu","year":"2023","unstructured":"Liu Y, Wu J, Ji Z, Chen L, Zou J, Zheng J et al (2023) Comparative efficacy and safety of different combinations of three CDK4\/6 inhibitors with endocrine therapies in HR+\/HER-2\u2009-\u2009metastatic or advanced breast cancer patients: a network meta-analysis. BMC Cancer 23(1):816. https:\/\/doi.org\/10.1186\/s12885-023-11322-2","journal-title":"BMC Cancer"},{"key":"7935_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15184558","author":"JJ Zhao","year":"2023","unstructured":"Zhao JJ, Fong KY, Chan YH, Tey J, Dawood S, Lee SC et al (2023) Indirect treatment comparison of first-line CDK4\/6-inhibitors in post-menopausal patients with HR+\/HER2- metastatic breast cancer. Cancers (Basel) 15(18):4558. https:\/\/doi.org\/10.3390\/cancers15184558","journal-title":"Cancers (Basel)"},{"key":"7935_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102915","volume":"78","author":"BE Wilson","year":"2024","unstructured":"Wilson BE, Booth CM (2024) Real-world data: bridging the gap between clinical trials and practice. EClinicalMedicine 78:102915. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102915","journal-title":"EClinicalMedicine"},{"issue":"8","key":"7935_CR16","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1093\/oncolo\/oyac089","volume":"27","author":"ES Knudsen","year":"2022","unstructured":"Knudsen ES, Schultz E, Hamilton D, Attwood K, Edge S, O\u2019Connor T et al (2022) Real-world experience with CDK4\/6 inhibitors for metastatic HR+\/HER2- breast cancer at a single cancer center. Oncologist 27(8):646\u2013654. https:\/\/doi.org\/10.1093\/oncolo\/oyac089","journal-title":"Oncologist"},{"issue":"10","key":"7935_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24108488","volume":"24","author":"M Cejuela","year":"2023","unstructured":"Cejuela M, Gil-Torralvo A, Castilla M, Dom\u00ednguez-Cejudo M, Falc\u00f3n A, Benavent M et al (2023) Abemaciclib, palbociclib, and ribociclib in real-world data: a direct comparison of first-line treatment for endocrine-receptor-positive metastatic breast cancer. Int J Mol Sci 24(10):8488. https:\/\/doi.org\/10.3390\/ijms24108488","journal-title":"Int J Mol Sci"},{"issue":"11","key":"7935_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13111938","volume":"13","author":"AI Miron","year":"2023","unstructured":"Miron AI, Anghel AV, Barnonschi AA, Mitre R, Liscu HD, G\u0103inariu E et al (2023) Real-world outcomes of CDK4\/6 inhibitors treatment in metastatic breast cancer in Romania. Diagnostics 13(11):1938. https:\/\/doi.org\/10.3390\/diagnostics13111938","journal-title":"Diagnostics"},{"issue":"1","key":"7935_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s44276-024-00070-w","volume":"2","author":"ML Gehrchen","year":"2024","unstructured":"Gehrchen ML, Berg T, Garly R, Jensen MB, E\u00dfer-Naumann S, R\u00f8nlev JD et al (2024) Real-world effectiveness of CDK 4\/6 inhibitors in estrogen-positive metastatic breast cancer. BJC Rep 2(1):44. https:\/\/doi.org\/10.1038\/s44276-024-00070-w","journal-title":"BJC Rep"},{"issue":"16 Suppl.","key":"7935_CR20","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1200\/JCO.2024.42.16_suppl.1067","volume":"42","author":"R Duchnowska","year":"2024","unstructured":"Duchnowska R, Soter K, Smok-Kalwat J, Grela-Wojewoda A, Winsko-Szcz\u0119snowicz K, Pogoda K et al (2024) Real-world treatment outcomes in patients with HR+ HER2- advanced breast cancer treated with CDK4\/6 inhibitors and endocrine therapy. J Clin Oncol 42(16 Suppl.):1067. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.1067","journal-title":"J Clin Oncol"},{"issue":"9","key":"7935_CR21","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1002\/ijc.35296","volume":"156","author":"M Thill","year":"2025","unstructured":"Thill M, Zahn MO, Welt A, Nusch A, Zaiss M, Engelken K et al (2025) Head-to-head comparison of palbociclib and ribociclib in first-line treatment of HR-positive\/HER2-negative metastatic breast cancer with real-world data from the OPAL registry. Int J Cancer 156(9):1770\u20131782. https:\/\/doi.org\/10.1002\/ijc.35296","journal-title":"Int J Cancer"},{"issue":"1","key":"7935_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12765-x","volume":"24","author":"T Dajsakdipon","year":"2024","unstructured":"Dajsakdipon T, Susiriwatananont T, Wongkraisri C, Ithimakin S, Parinyanitikul N, Supavavej A et al (2024) Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus AI in HR + \/HER2- advanced breast cancer (CEPRA study): preliminary analysis of real-world data from Thailand. BMC Cancer 24(1):1018. https:\/\/doi.org\/10.1186\/s12885-024-12765-x","journal-title":"BMC Cancer"},{"issue":"7","key":"7935_CR23","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.annonc.2025.03.023","volume":"36","author":"L Provenzano","year":"2025","unstructured":"Provenzano L, Dieci MV, Curigliano G, Giuliano M, Botticelli A, Lambertini M et al (2025) Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR+\/HER2- BC patients: results from the multicenter PALMARES-2 study. Ann Oncol 36(7):762\u2013774. https:\/\/doi.org\/10.1016\/j.annonc.2025.03.023","journal-title":"Ann Oncol"},{"issue":"1","key":"7935_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.104103","volume":"10","author":"HS Rugo","year":"2025","unstructured":"Rugo HS, Layman RM, Lynce F, Liu X, Li B, McRoy L et al (2025) Comparative overall survival of CDK4\/6 inhibitors plus an aromatase inhibitor in HR+\/HER2- metastatic breast cancer in the US real-world setting. ESMO Open 10(1):104103. https:\/\/doi.org\/10.1016\/j.esmoop.2024.104103","journal-title":"ESMO Open"},{"issue":"3","key":"7935_CR25","doi-asserted-by":"publisher","first-page":"402","DOI":"10.7326\/annals-24-01871","volume":"178","author":"MA Hern\u00e1n","year":"2025","unstructured":"Hern\u00e1n MA, Dahabreh IJ, Dickerman BA, Swanson SA (2025) The target trial framework for causal inference from observational data: why and when is it helpful? Ann Intern Med 178(3):402\u2013407. https:\/\/doi.org\/10.7326\/annals-24-01871","journal-title":"Ann Intern Med"},{"issue":"21","key":"7935_CR26","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1056\/NEJMp2407586","volume":"391","author":"RA Hubbard","year":"2024","unstructured":"Hubbard RA, Gatsonis CA, Hogan JW, Hunter DJ, Normand S-LT, Troxel AB (2024) \u201cTarget trial emulation\u201d for observational studies \u2014 potential and pitfalls. N Engl J Med 391(21):1975\u20131977. https:\/\/doi.org\/10.1056\/NEJMp2407586","journal-title":"N Engl J Med"},{"key":"7935_CR27","doi-asserted-by":"publisher","DOI":"10.1200\/cci.22.00140","volume":"7","author":"SA Kwee","year":"2023","unstructured":"Kwee SA, Wong LL, Ludema C, Deng CK, Taira D, Seto T et al (2023) Target trial emulation: a design tool for cancer clinical trials. JCO Clin Cancer Inform 7:e2200140. https:\/\/doi.org\/10.1200\/cci.22.00140","journal-title":"JCO Clin Cancer Inform"},{"issue":"6","key":"7935_CR28","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1093\/aje\/kwae346","volume":"194","author":"JR Rider","year":"2024","unstructured":"Rider JR, Wasserman A, Slipski L, Carrigan G, Harvey R, Jiao X et al (2024) Emulations of oncology trials using real-world data: a systematic literature review. Am J Epidemiol 194(6):1783\u20131793. https:\/\/doi.org\/10.1093\/aje\/kwae346","journal-title":"Am J Epidemiol"},{"issue":"4","key":"7935_CR29","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/pds.5565","volume":"32","author":"D Merola","year":"2023","unstructured":"Merola D, Young J, Schrag D, Lin KJ, Alwardt S, Schneeweiss S (2023) Effectiveness research in oncology with electronic health record data: a retrospective cohort study emulating the PALOMA-2 trial. Pharmacoepidemiol Drug Saf 32(4):426\u2013434. https:\/\/doi.org\/10.1002\/pds.5565","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"8","key":"7935_CR30","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1681\/ASN.0000000000000152","volume":"34","author":"EL Fu","year":"2023","unstructured":"Fu EL (2023) Target trial emulation to improve causal inference from observational data: what, why, and how? J Am Soc Nephrol 34(8):1305\u20131314. https:\/\/doi.org\/10.1681\/ASN.0000000000000152","journal-title":"J Am Soc Nephrol"},{"key":"7935_CR31","unstructured":"Flatiron Health: Database Characterization Guide. Flatiron.com. Published March 18, 2025. https:\/\/flatiron.com\/database-characterization. Accessed August 14, 2025."},{"issue":"4","key":"7935_CR32","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1111\/j.1541-0420.2005.00377.x","volume":"61","author":"H Bang","year":"2005","unstructured":"Bang H, Robins JM (2005) Doubly robust estimation in missing data and causal inference models. Biometrics 61(4):962\u2013973. https:\/\/doi.org\/10.1111\/j.1541-0420.2005.00377.x","journal-title":"Biometrics"},{"issue":"477","key":"7935_CR33","doi-asserted-by":"publisher","first-page":"846","DOI":"10.2307\/2290910","volume":"89","author":"J Robins","year":"1994","unstructured":"Robins J, Rotnitzky A, Zhao L (1994) Estimation of regression coefficients when some regressors are not always observed. J Am Statist Assoc 89(477):846\u2013866. https:\/\/doi.org\/10.2307\/2290910","journal-title":"J Am Statist Assoc"},{"issue":"3","key":"7935_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v045.i03","volume":"45","author":"S van Buuren","year":"2011","unstructured":"van Buuren S, Groothuis-Oudshoorn K (2011) mice: multivariate imputation by chained equations in R. J Stat Softw 45(3):1\u201367. https:\/\/doi.org\/10.18637\/jss.v045.i03","journal-title":"J Stat Softw"},{"key":"7935_CR35","unstructured":"Weberpals J. smdi: Perform Structural Missing Data Investigations. R package version 0.3.1. https:\/\/janickweberpals.gitlab-pages.partners.org\/smdi\/. 2024. Accessed February 26, 2026."},{"issue":"4","key":"7935_CR36","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele TJ, Ding P (2017) Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med 167(4):268\u2013274. https:\/\/doi.org\/10.7326\/M16-2607","journal-title":"Ann Intern Med"},{"issue":"5","key":"7935_CR37","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/pds.1200","volume":"15","author":"S Schneeweiss","year":"2006","unstructured":"Schneeweiss S (2006) Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf 15(5):291\u2013303. https:\/\/doi.org\/10.1002\/pds.1200","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"7935_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol32010052","volume":"32","author":"R Patel","year":"2025","unstructured":"Patel R, Mathews J, Hamm C, Kulkarni S, Gupta R, Opperman T et al (2025) Real-world experience with CDK4\/6 inhibitors in the first-line palliative setting for HR+\/HER2- advanced breast cancer. Curr Oncol 32(1):52. https:\/\/doi.org\/10.3390\/curroncol32010052","journal-title":"Curr Oncol"},{"issue":"10","key":"7935_CR39","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2217\/fon-2022-1287","volume":"19","author":"S Kahraman","year":"2023","unstructured":"Kahraman S, Erul E, Seyyar M, Gumusay O, Bayram E, Demirel BC et al (2023) Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive\/HER2-negative metastatic breast cancer. Future Oncol 19(10):727\u2013736. https:\/\/doi.org\/10.2217\/fon-2022-1287","journal-title":"Future Oncol"},{"key":"7935_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2024.100818","volume":"40","author":"J Coutinho-Almeida","year":"2024","unstructured":"Coutinho-Almeida J, Silva AS, Redondo P, Rodrigues PP, Ferreira A (2024) CDK4\/6 inhibitors and endocrine therapy in the treatment of metastatic breast cancer: a real-world and propensity score-adjusted comparison. Cancer Treat Res Commun 40:100818. https:\/\/doi.org\/10.1016\/j.ctarc.2024.100818","journal-title":"Cancer Treat Res Commun"},{"key":"7935_CR41","doi-asserted-by":"publisher","DOI":"10.1200\/CCI.23.00046","volume":"8","author":"EH Castellanos","year":"2024","unstructured":"Castellanos EH, Wittmershaus BK, Chandwani S (2024) Raising the bar for real-world data in oncology: approaches to quality across multiple dimensions. JCO Clin Cancer Inform 8:e2300046. https:\/\/doi.org\/10.1200\/CCI.23.00046","journal-title":"JCO Clin Cancer Inform"},{"issue":"6","key":"7935_CR42","doi-asserted-by":"publisher","first-page":"4460","DOI":"10.1111\/1475-6773.12872","volume":"53","author":"MD Curtis","year":"2018","unstructured":"Curtis MD, Griffith SD, Tucker M, Taylor MD, Capra WB, Carrigan G et al (2018) Development and validation of a high-quality composite real-world mortality endpoint. Health Serv Res 53(6):4460\u20134476. https:\/\/doi.org\/10.1111\/1475-6773.12872","journal-title":"Health Serv Res"},{"issue":"1","key":"7935_CR43","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/annonc\/mdt429","volume":"25","author":"MP Ufen","year":"2014","unstructured":"Ufen MP, K\u00f6hne CH, Wischneswky M, Wolters R, Novopashenny I, Fischer J et al (2014) Metastatic breast cancer: are we treating the same patients as in the past? Ann Oncol 25(1):95\u2013100. https:\/\/doi.org\/10.1093\/annonc\/mdt429","journal-title":"Ann Oncol"},{"issue":"7","key":"7935_CR44","doi-asserted-by":"publisher","first-page":"e412","DOI":"10.1200\/JOP.18.00149","volume":"14","author":"MK Kirkwood","year":"2018","unstructured":"Kirkwood MK, Hanley A, Bruinooge SS, Garrett-Mayer E, Levit LA, Schenkel C et al (2018) The state of oncology practice in America, 2018: results of the ASCO practice census survey. J Oncol Pract 14(7):e412\u2013e420. https:\/\/doi.org\/10.1200\/JOP.18.00149","journal-title":"J Oncol Pract"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07935-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-07935-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07935-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T21:02:13Z","timestamp":1773522133000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-07935-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,7]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["7935"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-07935-3","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,7]]},"assertion":[{"value":"15 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"22"}}